The short version, then the detail
Ozempic is semaglutide, a GLP-1 receptor agonist approved by the FDA in 2017 for type 2 diabetes (the same molecule at a higher dose is sold as Wegovy for weight management). It is one of the most heavily studied medications of the last decade. That doesn't make it risk-free — no effective medication is — but it means the risks are well characterized. Below is what the approved label and the major trials say, in plain terms.
The boxed warning: thyroid tumors
Ozempic carries a boxed warning — the FDA's strongest — about thyroid C-cell tumors. The basis is animal data: in rodents, semaglutide caused dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Crucially, the label states that whether this happens in humans is unknown; the human relevance has not been determined. It is a precaution, not proof of human harm. Because of it, Ozempic is contraindicated for anyone with a personal or family history of MTC or with MEN 2.
Who should not take it
The label lists exactly two contraindications:
- Personal or family history of medullary thyroid carcinoma, or MEN 2.
- A serious hypersensitivity (allergic) reaction to semaglutide or any ingredient.
Beyond those hard stops, your prescriber uses judgment for a history of pancreatitis or gallbladder disease, severe GI disease, diabetic retinopathy, insulin or sulfonylurea use (higher low-blood-sugar risk), and pregnancy or breastfeeding (avoid). See our drug-interactions overview for combinations that need care.
Common side effects — the real numbers
The frequent side effects are gastrointestinal and dose-dependent. From the Ozempic label, at the 1 mg dose:
| Side effect | 0.5 mg | 1 mg |
|---|---|---|
| Nausea | 15.8% | 20.3% |
| Vomiting | 5.0% | 9.2% |
| Diarrhea | 8.5% | 8.8% |
| Abdominal pain | 7.3% | 5.7% |
| Constipation | 5.0% | 3.1% |
Most are mild to moderate and tend to settle as your body adjusts. Slow dose escalation and smaller, lower-fat meals are the usual ways to reduce them.
Serious but rare risks
The label's warnings and precautions — uncommon, but worth recognizing early:
Acute pancreatitis
Severe, persistent abdominal pain (sometimes radiating to the back), with or without vomiting — stop and seek care.
Acute gallbladder disease
Rapid weight loss raises gallstone risk; upper-right abdominal pain, fever, or yellowing skin warrant evaluation.
Acute kidney injury
Usually a consequence of dehydration from vomiting/diarrhea — stay hydrated and report persistent GI symptoms.
Low blood sugar
Mainly when combined with insulin or a sulfonylurea; those doses may need adjusting.
Diabetic retinopathy & NAION
Retinopathy can transiently worsen with fast glucose lowering; the EMA lists the rare optic-nerve condition NAION as "very rare." See our eyes guide.
For the rare eye risks specifically, see our dedicated GLP-1 and eye health guide.
What about the heart?
Ozempic's own on-label evidence is SUSTAIN-6 (NEJM, 2016), where semaglutide cut major cardiovascular events by 26% in people with type 2 diabetes and high cardiovascular risk. At the higher 2.4 mg dose (marketed as Wegovy, not Ozempic), the SELECT trial (NEJM, 2023) of over 17,000 adults with cardiovascular disease and overweight/obesity but not diabetes showed a 20% reduction in major cardiovascular events (6.5% vs 8.0%). Either way, on the heart the evidence points to benefit, not harm.
The honest bottom line
Ozempic is well studied, and for appropriate patients the benefits generally outweigh the risks — most side effects are GI and manageable, serious events are rare, and there is a demonstrated cardiovascular benefit at the higher dose. The boxed warning is precautionary and rooted in rodent data, not confirmed human harm. Whether it's safe for you depends on your history — thyroid, pancreas, kidneys, eyes, other medications, and pregnancy plans — which is exactly what a prescriber is there to assess.
This page is educational and reflects the FDA-approved label and published trials as of 2026-07-17. It is not medical advice and can't account for your personal history — decide with a licensed clinician.